FDA Expands Test for Gastric and Esophageal Cancers - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands Test for Gastric and Esophageal Cancers

According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.

  • By

  • Kathryn Wighton

  • July 14, 2026

  • 2 min

Share

Original Source(s)

FDA Expands Test for Gastric and Esophageal Cancers

  • by Kathryn Wighton

  • July 14, 2026

Related Content

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.

Top 10 Evidence-Based Essentials in Pathology

A structured framework of diagnostic classifications, reporting frameworks, staging systems, coding resources, and molecular pathology tools used in practice.

A multidisciplinary RNA-guided approach to complement genomic analysis of unsolved patients with an inborn error of immunity